Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus “Buy” Recommendation From Analysts
Shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS – Get a rating) received a consensus buy recommendation from the six analysts who currently cover the stock, reports MarketBeat Ratings. One equity research analyst rated the stock with a hold rating and five issued a buy rating on the company. The 12-month average price target among brokerages that have quoted the stock over the past year is $36.00.
A number of equity research analysts have published reports on ACRS stocks. Cantor Fitzgerald reissued an “overweight” rating on Aclaris Therapeutics shares in a research report on Friday, February 25. Zacks Investment Research moved shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a Monday, Jan. 17 research report. SVB Leerink reissued a “buy” rating and posted a $26.00 price target on Aclaris Therapeutics shares in a research report on Thursday, December 9. Finally, HC Wainwright reiterated a “buy” rating and issued a target price of $50.00 on Aclaris Therapeutics shares in a research note on Monday, December 20.
ACRS stock opened Wednesday at $17.25. Aclaris Therapeutics has a 12-month low of $9.26 and a 12-month high of $30.38. The company has a market capitalization of $1.06 billion, a price-earnings ratio of -10.58 and a beta of 0.45. The company has a 50-day moving average of $13.20 and a 200-day moving average of $14.66.
Aclaris Therapeutics (NASDAQ: ACRS – Get a rating) last released its quarterly earnings data on Wednesday, February 23. The biotech company reported ($0.37) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.36) by ($0.01). The company posted revenue of $1.50 million for the quarter, compared to $1.80 million for analysts. Aclaris Therapeutics recorded a negative return on equity of 47.82% and a negative net margin of 1,343.96%. Aclaris Therapeutics revenue for the quarter decreased 5.1% year-over-year. As a group, equity research analysts expect Aclaris Therapeutics to post -1.84 earnings per share for the current year.
In other Aclaris Therapeutics news, CFO Frank Ruffo sold 12,823 shares of the company in a trade on Thursday, March 10. The stock was sold at an average price of $15.55, for a total value of $199,397.65. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink. Also, CEO neal walker sold 56,303 shares of the company in a transaction dated Friday, March 11. The stock was sold at an average price of $15.91, for a total transaction of $895,780.73. Disclosure of this sale can be found here. Last quarter, insiders sold 96,674 shares of the company valued at $1,526,797. Insiders hold 8.20% of the shares of the company.
Several institutional investors and hedge funds have recently changed their positions in the company. Point72 Hong Kong Ltd bought a new position in shares of Aclaris Therapeutics in the fourth quarter for a value of around $26,000. Macquarie Group Ltd. acquired a new position in Aclaris Therapeutics in the third quarter worth approximately $28,000. UBS Group AG increased its equity stake in Aclaris Therapeutics by 130.0% during the third quarter. UBS Group AG now owns 1,650 shares of the biotech company valued at $30,000 after buying an additional 7,151 shares last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Aclaris Therapeutics in Q3 worth $43,000. Finally, Royal Bank of Canada increased its stake in Aclaris Therapeutics by 73.0% in the third quarter. Royal Bank of Canada now owns 5,146 shares of the biotech company worth $93,000 after buying 2,172 more shares last quarter. 98.62% of the shares are currently held by institutional investors.
About Aclaris Therapeutics (Get a rating)
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company that engages in the identification, development and commercialization of new drugs to meet the needs of medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Aclaris Therapeutics right now?
Before you consider Aclaris Therapeutics, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Aclaris Therapeutics wasn’t on the list.
Although Aclaris Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here